<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>BiomX ( (PHGE) ) has shared an update. In the first quarter of 2026, BiomX completed a fundamental strategic overhaul, halting all clinical trials, winding down its U.S. phage unit and exiting its legacy biotech operations after its former core subsidiary, BiomX Ltd., entered insolvency in Israel in December 2025. The company replaced its entire management team and board, installed a new CEO and CFO, and adopted an acquisition-led strategy to build a diversified defense and security technology platform. BiomX now controls three main subsidiaries: DFSL, which offers high-accuracy LADAR-based counter‑UAS and perimeter detection systems; Zorronet, which provides AI-driven security and command-and-control middleware; and X Security &amp; Defense, which is being funded to develop distribution for aerial firefighting and first-response technologies. Zorronet has already secured pilots and classified projects with Elbit and Rafael and signed distribution deals in the U.S., Mexico, the UAE and Israel, positioning the group for early revenue, though much of its near-term income will depend on a handful of defense-related customers. The company’s transformation comes with sizable risks, including limited operating history in defense markets, dependence on successful integration of acquisitions, customer concentration and heavy exposure to Israeli regulatory and geopolitical conditions. It is also working to address a March 25, 2026 non-compliance notice from NYSE American tied to stockholders’ equity, while managing potential dilution from warrants and convertible securities and navigating volatile regional security, export controls and supply-chain pressures that could affect operations and growth. The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page. Spark’s Take on PHGE Stock According to Spark, TipRanks’ AI Analyst, PHGE is a Neutral. The score is held down primarily by weak financial performance (no revenue, persistent cash burn, and negative equity) and very poor technical trend/momentum (well below key moving averages with negative MACD). Corporate events are mixed—strategic security-tech acquisitions and a new supply deal help, but delisting risk/going-concern concerns and dilution-related actions materially offset those positives. To see Spark’s full report on PHGE stock, click here. More about BiomX BiomX Inc., formerly a clinical-stage biopharmaceutical company, has pivoted into a holding company focused on advanced defense, security and critical infrastructure technologies. After discontinuing its phage therapy programs in December 2025 and losing control of its insolvent Israeli biotech subsidiary, the Delaware-based firm now operates mainly through three Israeli units active in LADAR-based detection, AI-powered security software and first-response systems. The group’s portfolio targets fast-growing niches such as counter‑drone systems, AI-enabled command-and-control, perimeter and border security, wide-area surveillance and aerial firefighting. Its customer base now includes Israeli defense agencies, prime contractors like Elbit Systems and Rafael, transportation operators, municipalities and critical infrastructure providers, with revenues expected to be concentrated among a small number of large defense and security accounts. Average Trading Volume: 203,836 Technical Sentiment Signal: Sell Current Market Cap: $7.58M For a thorough assessment of PHGE stock, go to TipRanks’ Stock Analysis page.</div>

PHGE

IBBQ

LABU

ARKG

BiomX has undergone a strategic overhaul, exiting its legacy biotech operations and transitioning to a diversified defense technology platform. The company has replaced its management team and adopted an acquisition-led strategy, controlling three subsidiaries focused on defense technologies. Despite securing early revenue opportunities, BiomX faces risks including limited operating history, customer concentration, and regulatory challenges. The stock is rated as a Buy with a $26.00 price target, but analysts express concerns over financial performance and potential dilution risks.

BiomX Reinvents Itself as Diversified Defense Technology Platform